Journal
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Volume 3, Issue 6, Pages 783-803Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425255.3.6.783
Keywords
cancer; chemotherapy; drug-metabolising enzymes; tumoural drug metabolism
Ask authors/readers for more resources
Drug-metabolising enzymes (DMEs) are present in tumours and are capable of biotransforming a variety of anti neoplastics. Tumoural drug metabolism is both a potential mechanism of resistance and a means of achieving optimal therapy. This review addresses the classes of DMEs, their cytotoxic substrates and distribution in specific malignancies. The limitations of preclinical and clinical studies are highlighted. Their role in predicting therapeutic response, the activation of prodrugs and the potential for their modulation for gain is also addressed. The contribution of tumoural DMEs to cancer therapy can only be ascertained through large prospective studies and supported by new technologies. Only then can efforts be concentrated in the design of better prodrugs or combination therapy to optimise individual therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available